# Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

> clinical trial · VERIFIED · 2026-06-04

Status: RECRUITING · Sponsor: Beijing Biotech · Condition: Pancreatic Ductal Adenocarcinoma (PDAC)

- Company: Beijing Biotech
- Sector: cell therapy
- Primary source: https://clinicaltrials.gov/study/NCT07627711

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.